Procalcitonin
15
2
2
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
7%
1 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (15)
Evaluation of the Clinical Relationship Between Procalcitonin Level and Bacteremia Agent in Intensive Care Unit Patients
Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.
PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis
Predictive Value of Procalcitonin for Bacteremia in the ICU
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
Comparison of Salivary Procalcitonin (PCT) Levels and Serum PCT Levels
Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Procalcitonin Test for Differentiation of the Cause of Pneumonia
Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Procalcitonin and Postoperative Outcome After Open-heart Surgery
Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis
Procalcitonin as a Marker of Infection in Cancer Patients
Prospective Review of Procalcitonin After Cardiac Surgery
Impact of Procalcitonin on the Management of Children Aged 1 to 36 Month Presenting With a Fever Without a Source